Eagle is a specialty pharmaceutical company focused on developing injectable products, primarily in the areas of critical care, orphan diseases, and oncology. Our goal is to provide safer and more convenient solutions for patients and healthcare professionals with optimized formulations. We develop proprietary enhancements to FDA-approved drugs utilizing the 505(b)(2) regulatory pathway. This strategy expedites time for development, FDA review, and approval. We further seek to extend the patent life of our products through orphan drug exclusivity, new intellectual property protection, and/or 3 years of non-patent regulatory exclusivity. These last allowances come by way of the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch Waxman Act.